Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination Gene Therapy with AAV-Based Vectors Ameliorates the Phenotype of Type 2 Diabetes in Diet-Induced Obese and db/db Mice.

Molecular pharmaceutics - 4 May 2026

Rajendiran Ramkumar, Pathak Subhajit, Kumar Ashish, Bhaumik Soumita, Amit Sonal, Pydi Sai Prasad, Jayandharan Giridhara R

Abstract excerpt

Type 2 diabetes mellitus (T2DM) has significant treatment challenges due to its complex pathophysiology and associated comorbidities. In recent years, hepatokine fibroblast growth factor 21 (FGF21) has gained significant attention for treatment of metabolic disorders. Its translation potential is hindered by a short half-life and adverse effects on skeletal muscle. To address this, we developed an engineered AAV8...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Dependovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diet, High-Fat

Share to Fibroblast Growth Factors

Share to Genetic Therapy

Share to Insulin

Share to Insulin Resistance

Share to Mice, Obese

Source

Identifiers

PMID: 42011518
DOI: 10.1021/acs.molpharmaceut.5c01896

Genes

FGF21

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination Gene Therapy with AAV-Based Vectors Ameliorates the Phenotype of Type 2 Diabetes in Diet-Induced Obese and db/db Mice.PMID 42011518Read ↗

Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapySemantic proximity Read ↗

Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319.Semantic proximity Read ↗

Fibroblast growth factor-21 induces skeletal muscle atrophy and increases plasma amino acids in female mice: a potential role for glucocorticoidsSemantic proximity Read ↗

A single combination gene therapy treats multiple age-related diseases.Semantic proximity Read ↗

IGF-1/GH axis enhances losartan treatment in Lama2-related muscular dystrophySemantic proximity Read ↗

Developing a second-generation clinical candidate AAV vector for gene therapy of familial hypercholesterolemiaSemantic proximity Read ↗

Targeting Visceral Fat by Intraperitoneal Delivery of Novel AAV Serotype Vector Restricting Off-Target Transduction in LiverSemantic proximity Read ↗

A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.Semantic proximity Read ↗

miR-21 blocks obesity in mice: a potential therapy for humansSemantic proximity Read ↗

Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.Semantic proximity Read ↗

Combination of 20(R)-Rg3 and HUCMSCs Alleviates Type 2 Diabetes Mellitus in C57BL/6 Mice by Activating the PI3K/Akt Signaling PathwaySemantic proximity Read ↗

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.